L3VLUP
ProSign in

ARVN · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ARVNJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ARVN
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterARVNJNJ
Q3 2020none listed holders, n.a.30 holders, $26.2bn
Q4 20208 holders, $615m32 holders, $26.6bn
Q1 20215 holders, $162m31 holders, $25.3bn
Q2 20216 holders, $639m37 holders, $25.6bn
Q3 20215 holders, $693m40 holders, $24.1bn
Q4 20214 holders, $644m33 holders, $25.2bn
Q1 20222 holders, $542m35 holders, $28.2bn
Q2 20222 holders, $20m33 holders, $26.9bn
Q3 20223 holders, $107m36 holders, $25.4bn
Q4 20222 holders, $1.1m35 holders, $27.6bn
Q1 20232 holders, $2.2m42 holders, $24.5bn
Q2 20232 holders, $4.4m38 holders, $25.0bn
Q3 20232 holders, $4.7m37 holders, $18.9bn
Q4 20236 holders, $229m31 holders, $19.0bn
Q1 20245 holders, $227m32 holders, $19.7bn
Q2 20243 holders, $22m35 holders, $20.4bn
Q3 20242 holders, $21m28 holders, $22.3bn
Q4 20242 holders, $26m37 holders, $20.4bn
Q1 2025none listed holders, n.a.32 holders, $20.5bn
Q2 20253 holders, $19m31 holders, $18.4bn
Q3 20252 holders, $18m32 holders, $23.7bn
Q4 20252 holders, $19m29 holders, $27.8bn
Q1 20261 holders, $2.8m34 holders, $35.6bn
Q2 20261 holders, $684k33 holders, $39.1bn
ARVN

Arvinas Inc

Holders
3
Reported value
$19m
Buyers
3
Sellers
0

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
31
Reported value
$18.4bn
Buyers
15
Sellers
16

Breadth -1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 32 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ARVN (1)

Schonfeld Strategic Advisors LLC

Only JNJ (29)

AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, Fidelity (FMR LLC), GAMCO Investors Inc, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Point72 Asset Management LP, Quantbot Technologies LP, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, and 4 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →